Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS–1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I Study

Coutré, Steven; P. Leonard, John; R. Furman, Richard; C. Barrientos, Jacqueline; de Vos, Sven; W. Flinn, Ian; T. Schreeder, Marshall; D. Wagner‐Johnston, Nina; P. Sharman, Jeff; E. Boyd, Thomas; Fowler, Nathan; Holes, Leanne; J. Lannutti, Brian; M. Johnson, Dave; L. Miller, Langdon; M. Jahn, Thomas

doi:10.1182/blood.v120.21.191.191

Public

Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS–1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I Study

Published in Blood • Nov 16, 2012

Authors:

Steven Coutré

John P. Leonard

Richard R. Furman

Abstract

Abstract Abstract 191 Introduction: PI3Kdelta drives proliferation and survival in malignant B-cells. GS-1101 is an orally bioavailable, small-molecule inhibitor of PI3Kdelta that has shown considerable monotherapy activity when given at dose levels of 3100 mg BID in patients with heavily pretreated...

Subject

Bendamustine

Medicine

Rituximab

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!